Lupin and Boehringer Ingelheim inked a licensing, development and commercialisation agreement in 2019 for the Indain company#39;s novel oncology compound for difficult-to-treat cancers.from Moneycontrol Business News https://ift.tt/3wFaSa7
Thursday, May 27, 2021
Lupin gets $50 million from Boehringer Ingelheim as #39;milestone payment#39; for anti-cancer drug
Lupin and Boehringer Ingelheim inked a licensing, development and commercialisation agreement in 2019 for the Indain company#39;s novel oncology compound for difficult-to-treat cancers.from Moneycontrol Business News https://ift.tt/3wFaSa7
Subscribe to:
Post Comments (Atom)
-
The value had touched a high of 22% of total market capitalisation of listed firms in June 2009, dropping to a low of 5.1% in September 2020...
-
Huawei faces international scrutiny over its ties with the Chinese government and suspicion that Beijing could use Huawei#39;s technology f...
No comments:
Post a Comment